Primary prevention with pravastatin for 5 years continued to prevent coronary events in the following 10 years

Eaton, Charles B.
March 2008
ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p5
Academic Journal
The article focuses on the clinical trial investigating if five years of pravastatin treatment have long-term benefits for prevention of coronary heart disease (CHD) in middle-aged men with hypercholesterolemia and no history of myocardial infarction (MI). The trial, conducted with 6595 men (45 to 64 years of age), concluded that in middle-aged men with hypercholesterolemia and no history of MI, five years of pravastatin treatment continued to prevent CHD events in the following 10 years.


Related Articles

  • Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years. Woodend, A. Kirsten // Evidence Based Nursing;Apr2008, Vol. 11 Issue 2, p52 

    The article focuses on a study which found that 5 years of treatment with pravastatin continued to prevent coronary events in the following 10 years. The study was participated by 6,595 middle-aged men with hypercholesterolaemia and no history of myocardial infarction. 39% of the patients...

  • Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study. Barry, Sarah J. E.; Dinnett, Eleanor; Kean, Sharon; Gaw, Allan; Ford, Ian // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Background: Routinely collected electronic patient records are already widely used in epidemiological research. In this work we investigated the potential for using them to identify endpoints in clinical trials. Methods: The events recorded in the West of Scotland Coronary Prevention Study...

  • Modular prevention of heart disease following acute coronary syndrome (ACS) [ISRCTN42984084]. Redfern, Julie; Ellis, Elizabeth; Briffa, Tom; Freedman, SB // BMC Cardiovascular Disorders;2006, Vol. 6, p26 

    Background: Coronary heart disease (CHD) is a major cause of morbidity and mortality in Australia and it is recommended that all persons with unstable angina (UA) or myocardial infarction (MI) participate in secondary prevention as offered in cardiac rehabilitation (CR) programs. However, the...

  • Far from the Heart: Receptor cross-talk in remote conditioning. Weber, Christian // Nature Medicine;Jul2010, Vol. 16 Issue 7, p760 

    The article discusses a clinical trial on remote ischemic conditioning that could help in reducing or preventing myocardial infarction. It cites the mechanisms that the researchers used in the study such as occlusion and reperfusion. It elaborates the role of cell as well as morphine and opioid...

  • Placing COURAGE in Context: Review of the Recent Literature on Managing Stable Coronary Artery Disease. Coylewright, Megan; Blumenthal, Roger S.; Post, Wendy // Mayo Clinic Proceedings;Jul2008, Vol. 83 Issue 7, p799 

    Coronary artery disease (CAD) is the leading cause of death in the United States, but prevention and intervention efforts are lowering mortality. This progress is being undercut by rising rates of obesity and diabetes, and adherence to evidence-based prevention efforts is less than ideal. Many...

  • Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Costa, João; Borges, Margarida; David, Cláudio; Vaz Carneiro, António // BMJ: British Medical Journal (International Edition);5/13/2006, Vol. 332 Issue 7550, p1115 

    Objective To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention. Design Systematic review and meta-analysis. Data sources Cochrane, Medline, Embase, and reference lists up to April 2004. Study...

  • Lifestyle changes reduce cardiovascular risk. Ryan, Patricia // Research Review (International Council on Active Aging);Apr2012, Vol. 12 Issue 13, p4 

    The article discusses the results of Heart of New Ulm Project, aimed at reducing heart attacks and coronary heart disease in New Ulm, Minnesota, that found reductions in factors including smoking, stress levels and hypertension, as well as in hyperlipidemia, and fasting glucose.

  • Cardiovascular disease: microRNA protects the heart. Kingwell, Katie // Nature Reviews Drug Discovery;Feb2011, Vol. 10 Issue 2, p98 

    The article discusses research concerning the reduction of myocardial infarction's effects through microRNA (miRNA) miR-499. It references the study "mIr-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1," by J.-X. Wang and colleagues in the 2011 issue...

  • Treating average cholesterol levels in patients with coronary heart disease. Lindbloom, Erik J. // Journal of Family Practice;Feb1999, Vol. 48 Issue 2, p94 

    The article cites a research study that investigates whether reduction of average cholesterol levels with pravastatin in patients with coronary heart disease (CHD) can reduce mortality and cardiovascular events. This multicenter trial recruited patients aged 31 to 75 years in Australia and New...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics